Chronic Lymphocytic Leukemia (CLL): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, characterized by clonal accumulation of functionally incompetent small mature-appearing CD5+/CD19+/CD23+ B lymphocytes in the peripheral blood, bone marrow, lymph nodes, and spleen. Approximately 21,000 new cases are diagnosed annually in the US; median age at diagnosis is 70 years, and it is rare under age 40. CLL biology is highly variable: approximately 30% of patients require treatment within 5 years, while another 30% never require treatment during their lifetime. The discovery that CLL cells express CD20 (rituximab target), BTK (ibrutinib, acalabrutinib, zanubrutinib target), and BCL-2 (venetoclax target) has transformed treatment: from cytotoxic chemoimmunotherapy to targeted oral agents achieving superior outcomes with manageable toxicity. Modern CLL management requires comprehensive molecular risk stratification including del(17p), TP53 mutation, and IGHV mutation status.

Risk factors for CLL include male sex (approximately 1.7:1 male-to-female ratio), age over 60, and first-degree family history of CLL or other lymphoproliferative disorders (8-fold increased risk in first-degree relatives — the highest familial risk of any leukemia). Agent Orange (dioxin) exposure is a recognized and established risk factor. No dietary, alcohol, or smoking-related risk factors have been definitively established. Pesticide exposure (organochlorines) is a suspected but unconfirmed risk factor. Most cases arise from acquired somatic mutations in B-cell precursors or mature B-cells with specific genetic changes: IGHV somatic hypermutation status determines biological behavior; unmutated IGHV (≥98% homology to germline) indicates more aggressive disease. Frequently mutated genes: TP53, ATM, NOTCH1, SF3B1, BIRC3, and MYD88. Monoclonal B-cell lymphocytosis (MBL, <5×10⁹/L clonal B-cells) is a precursor state to CLL, progressing to CLL at approximately 1-2% per year.

Up to 70-80% of CLL patients are asymptomatic at diagnosis, with disease identified incidentally on a routine complete blood count showing absolute lymphocytosis. When symptomatic, CLL presents with: progressive fatigue and exercise intolerance from anemia; symptomatic lymphadenopathy — painless, rubbery, progressive enlargement of cervical, axillary, inguinal, and mediastinal nodes; splenomegaly causing left upper quadrant fullness and early satiety; recurrent bacterial infections from hypogammaglobulinemia — sinopulmonary infections (pneumonia, sinusitis) are most common; and constitutional B symptoms (drenching night sweats, fever above 38°C, weight loss >10% in 6 months) in advanced or transforming disease. Autoimmune complications: autoimmune hemolytic anemia (AIHA, Coombs-positive) occurs in 10-15% of CLL patients; immune thrombocytopenic purpura (ITP) occurs in approximately 5%.

iwCLL 2018 diagnostic criteria: persistent absolute lymphocytosis of monoclonal B-cells ≥5×10⁹/L confirmed by peripheral blood flow cytometry demonstrating characteristic co-expression of CD5, CD19, CD23, dim surface immunoglobulin (IgM or IgD), and CD200, with low CD79b and absent FMC7. Small lymphocytic lymphoma (SLL) is the tissue counterpart with lymphadenopathy but blood lymphocytosis below 5×10⁹/L. Rai staging (0-IV) and Binet staging (A-C) classify disease extent using CBC and physical examination. Prognostic biomarkers mandatory: FISH panel for del(17p), del(11q), trisomy 12, del(13q14); TP53 mutation by sequencing; IGHV somatic hypermutation status (mutated = favorable, unmutated IGHV = poor prognosis); NOTCH1, SF3B1, and BIRC3 mutations; and serum beta-2-microglobulin. Bone marrow biopsy is not required for diagnosis but may be needed to evaluate cytopenias.

Watch-and-wait is the evidence-based standard for early asymptomatic disease (Rai 0-II, Binet A, no iwCLL criteria for treatment). First-line treatment is initiated when iwCLL active disease criteria are met. BTK inhibitors: ibrutinib 420 mg daily (continuous), acalabrutinib 200 mg daily, or zanubrutinib 320 mg daily — all are standard first-line and preferred for del(17p)/TP53-mutated CLL; acalabrutinib and zanubrutinib have improved cardiac safety profiles versus ibrutinib. Venetoclax plus obinutuzumab (CLL14 trial): 12-month time-limited therapy achieving MRD-negative complete remission in over 50% of patients, with 5-year PFS approximately 65%. Second-line: venetoclax plus rituximab (MURANO trial) for patients previously treated with CIT; or BTK inhibitor switch. Allogeneic SCT: reserved for Richter's transformation, BTK inhibitor-refractory disease, and del(17p)/complex karyotype in eligible patients. Intravenous immunoglobulin (IVIG) for recurrent severe bacterial infections due to hypogammaglobulinemia.

Prognosis in CLL is highly variable and closely linked to molecular risk stratification. Early-stage asymptomatic CLL (Rai 0, Binet A) with favorable biology — mutated IGHV, del(13q) as sole abnormality, no del(17p) or TP53 mutation — has a median OS exceeding 20-25 years, essentially normal life expectancy in many patients. Rai stage III-IV (anemia or thrombocytopenia) at diagnosis has historically carried a median OS of 4-6 years, substantially improved by targeted agents. Del(17p)/TP53-mutated CLL had very poor prognosis with chemoimmunotherapy (median OS 2-3 years with FCR); BTK inhibitors (ibrutinib, acalabrutinib) have transformed outcomes for this high-risk group, with 5-year PFS approximately 60-65% in del(17p) CLL. Venetoclax plus obinutuzumab (CLL14 trial) achieves MRD-negative complete remission in over 50% of patients, with 5-year PFS approximately 65% overall and approaching 70% for mutated IGHV patients; this represents a meaningful step toward long-term disease control. Richter's transformation to DLBCL occurs in 2-5% of CLL patients and carries a median OS of 8-12 months despite R-CHOP-based salvage. Key prognostic factors include IGHV mutation status (mutated IGHV is favorable, unmutated IGHV is adverse without targeted therapy), del(17p)/TP53 mutation (high risk), del(11q) (intermediate risk), del(13q) (favorable), serum beta-2-microglobulin, and complex karyotype. Allogeneic SCT offers potential cure for eligible younger patients with ultra-high-risk disease. Long-term monitoring includes CBC every 3-6 months, immunoglobulin levels for hypogammaglobulinemia warranting IVIG, and prompt evaluation of rapidly enlarging nodes to exclude Richter's transformation.

CLL is largely a disease of aging and genetic predisposition, and no modifiable preventive measures have been established for the general population. Agent Orange exposure is an established risk factor: veterans with Agent Orange exposure are eligible for VA disability benefits related to CLL, and avoiding dioxin-containing herbicides is a preventive consideration for at-risk occupational groups. Individuals with a positive family history of CLL — particularly first-degree relatives with CLL or other lymphoproliferative disorders — should inform their primary care physician, as they carry an 8-fold increased risk. Proactive screening with CBC is reasonable in this high-risk group. Monoclonal B-cell lymphocytosis (MBL) requires monitoring (annual CBC) but no treatment. Vaccination against pneumococcal disease and influenza is recommended for all CLL patients, ideally before starting immunosuppressive therapy. There is no known role for diet, exercise, or vitamin supplementation in CLL prevention.

See a physician promptly for: an unexplained finding of lymphocytosis on routine blood count — this should prompt lymphocyte count confirmation and peripheral blood flow cytometry to exclude CLL; persistently enlarged lymph nodes (especially in multiple sites) that do not resolve within 4-6 weeks; unusual fatigue or pallor unexplained by obvious causes; recurrent sinopulmonary infections (more than 2 bacterial infections requiring antibiotics per year suggests immune deficiency); or any rapidly enlarging lymph node mass or constitutional symptoms in a patient with known CLL — these may signal Richter's transformation, which requires urgent assessment. Established CLL patients must attend their scheduled monitoring appointments: CBC every 3-6 months for early-stage watch-and-wait patients, and immediately if they develop unexpected fever, weight loss, or rapidly enlarging nodes. Any CLL patient starting BTK inhibitor therapy should be advised to report new atrial fibrillation, bleeding, or hypertension promptly.